Please assess the completion status of the following clinical trial:

Trial Title: Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 20-70 yrs~* Gender: Male and female~* Systemically healthy: Physical status according to the American Society of Anesthesiologists (ASA) I or II~* Requiring sinus augmentation to allow dental implant placement~* Missing teeth: Maxillary second premolar, maxillary first molar and/or maxillary second molar~* Remaining alveolar bone height: 2 to 6 mm~* Must be able and willing to follow study procedures and instructions~* Must have read, understood and signed an informed consent form~Exclusion Criteria:~* Allergies or hypersensitivities to study related medications: dexamethasone, chlorhexidine, ibuprofen. For patients allergic to amoxicillin a comparable substitute antibiotic will be used~* Hematologic disorders/ blood dyscrasias~* Active infectious disease~* Liver or kidney dysfunction/failure- Patients will have blood drawn for serum laboratory tests, including creatinine, blood urea nitrogen, AST, ALT, and bilirubin. All of these must be within normal limits for a patient to be included in the study~* Laboratory values that will define normal renal and hepatic function, as well as criteria for exclusion of metabolic bone disease are consistent with those established by the University of Michigan Health System (UMHS). Normal clinical values will be used to help assure the health of all subjects in this trial. Potential subjects whose laboratory values fall outside the UMHS normal ranges and are considered clinically significant will be required to have medical clearance from their primary care provider prior to participation. Potential subjects presenting with clinically insignificant laboratory abnormalities will not require medical clearance and will be considered for inclusion in the study~* Endocrine disorders/dysfunctions (i.e. Type I and II diabetes)~* Cancer - The explicit definition of cancer used to exclude patients is consistent with that described by the National Cancer Institute (NCI), National Institutes of Health. According to NCI, cancer is any disease in which abnormal cells divide without control and invade nearby tissues (invasive disease). These include carcinomas, sarcomas, leukemias, and lymphomas. Any patient with a history of these invasive diseases will be excluded from the study.~* Patients who currently use bisphosphonates or have a history of bisphosphonate use will be excluded from the trial~* HIV+~* Metabolic Bone Diseases- Patients with metabolic bone diseases such as Paget's disease, hypercalcemia, moderate to severe vitamin D3 abnormalities or any other metabolic bone disease including osteoporosis and osteoporotic fractures will be excluded~* Pregnant women- Female patients who are of childbearing potential are excluded except those who are using hormonal or barrier methods of birth control (oral or parenteral contraceptives, diaphragm plus spermicide, or condoms). Pregnancy status will be determined with a urine test and patients who are pregnant will be excluded~* Patients with acute sinusitis, or presenting any sinus pathology that would contraindicate sinus augmentation~* Patients with congenital or metabolic bone disorders~* Current smokers (have smoked within 6 mos. of study onset)~* Subjects with congenital, or co-morbid conditions that would affect the study outcome or interpretation of study results will be excluded~* Individuals who have a BMI outside normal limits that deems them overweight (BMI \>25) will be excluded due to potential difficulties in locating appropriate surgical entry of the iliac crest during the bone marrow aspiration procedure~* Long term (\>2 weeks) use of antibiotics in the past 3 months~* Periodontally unstable subjects~* Subjects having any extractions in the possible treatment area in the past 3 months~* Subjects that are edentulous

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- sinus lift plus dental implant (Type: ACTIVE_COMPARATOR): Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: N/A; only sinus augmentation and dental implant
- sinus lift plus BRCs and dental implant (Type: EXPERIMENTAL): transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant

Based on this trial design, predict the completion outcome and termination type (if applicable).